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Abstract Indomethacin (INDO) has the potential to be a
useful tool to explore the influence of cerebral blood flow
and its responses to CO2 on ventilatory control. However,
the effect of INDO on the cerebrovascular and ventilatory
response to hypoxia remains unclear; therefore, we exam-
ined the effect of INDO on ventilatory and cerebrovascular
sensitivity to hypoxia and hypercapnia. We measured end-
tidal gases, ventilation ð _VEÞ; and middle cerebral artery
velocity (MCAv) before and 90 min following INDO
(100 mg) in 12 healthy participants at rest and during hy-
peroxic hypercapnia and isocapnic hypoxia. Following
INDO, resting _VE and end-tidal gases were unaltered
(P [ 0.05), whilst MCAv was lowered by 25 ± 19%
(P \ 0.001). INDO ingestion reduced MCAv-CO2 reac-
tivity by 46 ± 29% (2.9 ± 0.9 vs. 1.7 ± 0.9 cm s-1
mmHg-1; P \ 0.001) and enhanced the _VE-CO2 sensiti-
vity by 0.5 ± 0.5 L min-1 mmHg-1 (1.9 ± 1.5 vs. 2.3 ±
1.6 L min-1 mmHg-1; P \ 0.05). No changes were
observed in either the MCAv or _VE responsiveness to
isocapnic hypoxia following INDO ingestion (P [ 0.05).
These findings indicate that INDO does not alter cerebro-
vascular and ventilatory responsiveness to hypoxia, indi-
cating a preserved peripheral chemoreflex in response to
this pharmacological agent.
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Introduction
The net [H?] in the environment of central chemoreceptors
is dependent on the rate of CO2 production and the rate of
CO2 washout in the brain. The former is determined by
cerebral metabolism, whilst the latter is regulated by the
cerebral blood flow (CBF) response to changes in the
partial pressure of arterial CO2 (PaCO2) in the brain—
termed cerebrovascular CO2 reactivity. For example,
reduced resting CBF and blunted cerebrovascular CO2
reactivity have been shown to increase the jugular venous
PCO2 (Chapman et al. 1979a), whilst an increase in CBF
lowers brain tissue PCO2 (Fencl 1986). Accordingly, it has
been proposed that CBF and cerebrovascular CO2 reac-
tivity may help regulate central (i.e. brain) pH, and thus
affects the most important input to respiratory drive (cen-
tral chemoreceptor stimulus) (Chapman et al. 1979a;
Hohimer et al. 1985; Xie et al. 2006).
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Chapman et al. (1979a) previously reported that, in
unanaesthetised goats, a 30% reduction in CBF and cere-
brovascular CO2 reactivity (via carotid clamping) elevates
jugular venous PCO2 and augments the ventilatory
response to hyperoxic rebreathing, but not to transient
hypoxia. Since hyperoxia is known to silence the peripheral
chemoreceptor activity (Cunningham et al. 1963; Gardner
1980; Mohan and Duffin 1997), Chapman et al. (1979a)
proposed that a blunted cerebrovascular CO2 reactivity, by
attenuating the washout of H? from the brain, selectively
enhances the central chemoreflex without altering the
peripheral chemoreflex. In the same study, they also found
that further reductions in CBF (50%) and near abolishment
of cerebrovascular CO2 reactivity depresses both the cen-
tral and peripheral chemoreflexes, presumably due to the
hypoxic depression of respiratory neurons associated with
severe cerebral ischaemia (Chapman et al. 1979b). In
addition, Nishimura et al. (1987) provided evidence that
the cerebrovascular responsiveness to hypoxia modulates
the ventilatory responsiveness to hypoxia via H? washout
from the brain, thereby attenuating the central drive, at
least during moderate hypoxic exposure. Taken together,
these findings support the role of CBF and its responses to
CO2 and O2 in the control of breathing.
Indomethacin (INDO) is a potent reversible cyclooxy-
genase inhibitor, which has been shown to impair the
cerebral vessels’ ability to dilate in response to potent
vasodilatory stimulus such as hypercapnia and iloprost (a
prostacyclin receptor agonist) (Parfenova et al. 1994;
Parfenova et al. 1995b). Accordingly, the authors concluded
that INDO lowers CBF and cerebrovascular CO2 reactivity
by selective inhibition of prostaglandin H synthase and
prostacyclin receptor-mediated responses (Parfenova et al.
1995b). Moreover, numerous studies have found that INDO
lowers CBF and attenuates the cerebrovascular reactivity to
CO2 (Bruhn et al. 2001; Eriksson et al. 1983; Ivancev et al.
2009; Kastrup et al. 1999; Markus et al. 1994; St Lawrence
et al. 2002; Wennmalm et al. 1983) without concomitant
changes in cerebral metabolic rate (Hohimer et al. 1985;
Kraaier et al. 1992) or plasma catecholamines (Green et al.
1987; Staessen et al. 1984; Wennmalm et al. 1984).
Recently, it had been demonstrated that INDO (100 mg)
enhances the central chemoreflex (Fan et al. 2010; Xie et al.
2006), increases the propensity for apnoea during sleep in
healthy humans (Xie et al. 2009) and exacerbates the
severity of obstructive sleep apnoea (Burgess et al. 2010).
These changes in ventilatory control were attributed to the
INDO-induced reduction in cerebrovascular CO2 reactivity
and associated reduction in H? washout, resulting in an
increase in central chemoreceptor activation (Hohimer et al.
1985). Despite the numerous studies on the central che-
moreflex, however, the effect of INDO on peripheral che-
moreflex in humans is yet to be examined.
Animal studies have reported an enhanced carotid body
chemosensitivity to hypoxia and hypercapnia with INDO,
whilst no changes were observed under normoxic and
eucapnic conditions (Gomez-Nino et al. 1992, 1994). In
contrast, other studies have found that, since bilateral car-
otid section failed to abolish INDO-induced increases in
respiratory movement or _VE;, the effect of INDO on _VE is
unlikely to be mediated by the carotid bodies (Jansen et al.
1984; McQueen and Belmonte 1974). In healthy resting
humans, Xie et al. (2006) found that oral INDO caused a
37% reduction in cerebrovascular CO2 reactivity and a
40–60% increase in the _VE responsiveness to steady-state
hyperoxic hypercapnia and normoxic hypercapnia. Since
no differences were observed between the hyperoxic and
normoxic conditions, it was proposed that the observed
increase in ventilatory sensitivity to CO2 following INDO
was primarily due to an augmented central chemoreceptor
activation via reduced H? washout in the brainstem, rather
than any concurrent changes in peripheral chemoreflex
(Xie et al. 2006). However, since the nature of the inter-
actions between central and peripheral chemoreceptors is
yet unclear (Blain et al. 2009; Dahan et al. 2008; Day and
Wilson 2009), the findings by Xie et al. (2006) should be
interpreted with caution. As such, no studies have yet
examined the effect of INDO on the ventilatory respon-
siveness to hypoxia per se. Likewise, previous animal
studies have demonstrated that INDO blunts the CBF
response to hypoxia (cerebrovascular O2 reactivity) in a
dose-dependent manner (Coyle et al. 1993, 1995). How-
ever, the effect of INDO on the cerebrovascular reactivity
to hypoxia has not been previously examined in humans.
Since cerebrovascular hypoxic reactivity plays an impor-
tant role in modulating hypoxic ventilatory response
(Nishimura et al. 1987), INDO-induced changes in the
cerebrovascular O2 reactivity may account, in part, for any
potential alterations in the peripheral chemoreflex.
The purpose of this study was to examine the effect of
INDO on the CBF and _VE response to hypoxia in humans.
We examined the hypothesis that INDO-induced reduction
in cerebrovascular CO2 reactivity would augment _VE
responsiveness to CO2 without any concurrent alterations
in the cerebrovascular and ventilatory responsiveness to
hypoxia.
Methods
Participants
Twelve adults (8 male and 4 female) with a mean age of
30 ± 10 years (mean ± SD), and body mass index of
23 ± 2 kg m-2 participated in this study. Participants were
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non-smokers, had no previous history of cardiovascular,
cerebrovascular or respiratory diseases and were not taking
any medications. All participants were informed regarding
the purposes and procedures of this study, and informed
consent was given prior to participation. The study was
approved by the Lower South Regional Ethics Committee
of Otago and conformed to the standards set by the Dec-
laration of Helsinki.
Experimental design
The participants were required to visit the laboratory on
two occasions. After a full familiarisation with the exper-
imental procedures outlined below (visit one), participants
underwent one experimental trial (INDO). To account for
the time course effect, 7 of the 12 participant also under-
went a placebo trial (randomised order) separated by at
least 7 days. Both the INDO (100 mg) and placebo trials
were administered in identical-looking capsules and
ingested with 20 mL of antacid (Maalox). Before each
experimental session, participants were informed to abstain
from exercise and alcohol for 24 h, caffeine for 12 h and a
heavy meal for 4 h prior. Experiments were conducted at
the same time of day for each participant to reduce the
known influence of circadian rhythm on the key cardiore-
spiratory and cerebrovascular variables (Ainslie and Duffin
2009).
All experiments were performed with participants semi-
recumbent and with temperate controlled at 22C. Fol-
lowing 10–15 min of quiet rest, each experimental testing
session comprised: (a) instrumentation; (b) hyperoxic
hypercapnia and isocapnic hypoxia; (c) INDO/placebo
administration; (d) 90-min rest, and (e) repeat testing of (a)
and (b). The order of the hyperoxic hypercapnia and iso-
capnic hypoxia was randomised and full recovery (5 min)
was permitted between each trial to restore end-tidal gases
to baseline resting values.
Hyperoxic hypercapnia
The participants breathed through a leak-free respiratory
mask (Hans-Rudolph 8980, Kansas City, MO) attached to a
one-way non-rebreathing valve (Hans-Rudolph 2700). The
inspiratory line contained a Y-valve, which allowed
switching from room air to a 200-L Douglas bag containing
7% CO2 and 93% O2. The steady-state test began with
2 min of baseline room air breathing, before switching onto
the Douglas bag for 4 min.
Isocapnic hypoxia
Participants wore a nose clip and breathed through a
mouthpiece connected to a Y-valve allowing switching
from room air to a circuit consisting of a 6-L rebreathing
bag and a soda lime reservoir. Isocapnic hypoxia began
with 2-min baseline room air breathing, before participants
switched to the rebreathing circuit at the end of inspiration.
Isocapnic hypoxia was terminated when: (1) the partici-
pant’s peripheral O2 saturation (SpO2) reached 80%; (2) the
participant’s partial pressure of end-tidal O2 (PETO2)
reached 45 mmHg; (3) the participant’s _VE exceeded
100 L min-1; or (4) the participant reached the end of his
tolerance.
Measurements
Respiratory variables
Pulmonary _VE and its components, tidal volume (VT) and
breathing frequency (f), were measured using a heated
pneumotachograph (Hans-Rudolph HR800) and expres-
sed in units adjusted to BTPS. The fractional changes in
inspired and expired O2 and CO2 were used to calculate
partial pressure of end-tidal O2 and CO2 (PETCO2) with
fast responding gas analysers (AEI Technologies, Pitts-
burgh, PA). The pneumotachograph was calibrated using
a 3-L syringe (Hans-Rudolph 2700, Kansas City, MO)
and the gas analysers were calibrated using known
concentrations of O2 and CO2 prior to each testing
session.
Cerebrovascular and cardiovascular variables
Middle cerebral artery velocity (MCAv, an index of CBF)
was measured in the right middle cerebral artery using a
2-MHz pulsed Doppler ultrasound system (DWL Doppler,
Sterling, VA). The Doppler ultrasound probe was posi-
tioned over the right temporal window and held in place
with an adjustable plastic headband. The signals were
obtained using search techniques described elsewhere
(Aaslid et al. 1982). Frontal cortical cerebral oxygenation
was measured in seven participants using near-infrared
spectroscopy (NIRS) (NIRO-200; Hamamatsu Photonics;
Hamamatsu, Japan). A probe holder containing an emission
probe and detection probe was attached at the right side of
the forehead with a distance of 5 cm between the probes.
The methodology of this system has been described pre-
viously (Al-Rawi et al. 2001; Nollert et al. 1995). Heart
rate (HR) was determined using a three-lead ECG. Beat-
to-beat mean arterial blood pressure (MAP) was monitored
using finger photoplethysmography (Finometer, TPD Bio-
medical Instrumentation). To ensure accurate measure-
ments of MAP, right arm manual blood pressure
measurements by auscultation were also made periodically
to check and validate the automated recordings.
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Cerebrovascular conductance index (CVCi) was estimated
by dividing mean MCAv by MAP within each breath cycle
to reveal intrinsic vascular responses to CO2 (Claassen
et al. 2007). Peripheral O2 saturation (SpO2) was obtained
using a finger pulse oximeter.
Data analysis
Hyperoxic hypercapnia
_VE; MCAv and CVCi responsiveness to CO2 was estimated
from the slope of the mean value of each dependant vari-
able in the final minute of baseline and steady-state
hyperoxic hypercapnic breathing. Steady-state hypocapnic
cerebrovascular reactivity was estimated from the slope of
the mean MCAv in the final minute of baseline and vol-
untary hyperventilation prior to the rebreathing. It should
be acknowledged that the steady-state determination of
ventilatory CO2 sensitivity is restricted to the number of
data points used in the analysis (Mohan et al. 1999; Pandit
et al. 2007). However, the steady-state _VE-CO2 sensitivities
(control and INDO) observed in the present study (Fig. 1)
were comparable to those reported by Xie et al. (2006) who
used four steady-state data points (baseline, 2, 4 and 6%
CO2), thereby supporting the use of two data points in
estimating steady-state ventilatory CO2 sensitivity in the
present study.
Isocapnic hypoxia
To express the _VE and MCAv changes as a linear function
of the hypoxic stimulus during isocapnic hypoxia, PETO2
was converted to a calculated arterial O2 saturation (ScO2)
using the equation (Severinghaus 1979):
ScO2 ¼ PETO32 þ 150PETO2
 1 23; 400 þ 1
h i1
 100
where ScO2 is a percentage and PETO2 is in mmHg.
Changes in _VE and MCAv were then subsequently
plotted against ScO2 using linear regression to obtain the
respiratory and cerebrovascular responsiveness to hypoxia.
Statistical analysis
To assess the effect of INDO on resting variables, venti-
latory and cerebrovascular changes during hyperoxic
hypercapnia and isocapnic hypoxia, we used paired t test
with a-level of P \ 0.05 (SPSS version 17.0, SPSS, Chi-
cago, IL). Likewise, to assess the effect of placebo on
resting variables, ventilatory and cerebrovascular changes
during hyperoxic hypercapnia and isocapnic hypoxia, we
used paired t test with a-level of P \ 0.05.
Results
All 12 participants completed the placebo and INDO trial
with the hyperoxic hypercapnia and isocapnic hypoxia.
Baseline
Indomethacin ingestion reduced both MCAv and CVCi by
25 ± 19 and 31 ± 22%, respectively, from baseline
(P \ 0.001; Table 1), whilst no changes were observed
following placebo ingestion (P [ 0.05; Table 1). In con-
trast, placebo ingestion increased cerebral oxygenation by
4.7 ± 4.4% (P \ 0.05; Table 1), whilst no changes were
observed with INDO (P [ 0.05). Neither placebo nor
INDO altered any resting respiratory variables (P [ 0.05;
Table 1). INDO lowered resting HR by 8 ± 6 b min-1
(P \ 0.001), whilst MAP remained unchanged (P [ 0.05;
Table 1). Similarly, placebo lowered resting HR by
5 ± 4 b min-1 (P \ 0.01), whilst MAP was unchanged
(P [ 0.05; Table 1).
Cerebrovascular and ventilatory responsiveness
to hypercapnia and hypoxia
During the hyperoxic hypercapnia, INDO lowered the
MCAv-CO2 reactivity by 46 ± 29% (2.9 ± 0.9 versus
1.7 ± 0.9 cm s-1 mmHg-1; P \ 0.001; Fig. 1) and inc-
reased the _VE-CO2 sensitivity by 0.5 ± 0.5 L min
-1
mmHg-1 (1.9 ± 1.5 vs. 2.3 ± 1.6 L min-1 mmHg-1;
P \ 0.01), whilst no changes were observed with placebo
(P [ 0.05). No differences were observed in either the
MCAv-ScO2 reactivity or _VE-ScO2 sensitivity during iso-
capnic hypoxia following either placebo or INDO ingestion
(P [ 0.05; Fig. 2).
Discussion
The major findings from the present study are that INDO
selectively blunts the cerebrovascular CO2 reactivity and
enhances the ventilatory CO2 sensitivity without affecting
either the cerebrovascular or the ventilatory responsiveness
to hypoxia.
Methodological considerations
Indomethacin
Indomethacin was used in this study as a pharmacological
means to reduce cerebrovascular CO2 reactivity in healthy
resting humans without concomitant changes in cerebral
metabolic rate (Hohimer et al. 1985; Kraaier et al. 1992) or
plasma catecholamine concentrations (Green et al. 1987;
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Staessen et al. 1984; Wennmalm et al. 1984). Studies have
shown that the peak effect of INDO (100 mg) on reducing
MCAv occurs at *90 min and persists for[4 h following
ingestion (Markus et al. 1994; Xie et al. 2006). It is
therefore reasonable to assume that, in the present study,
both MCAv and the cerebrovascular CO2 reactivity would
be significantly attenuated for the duration of the
experimental trials following INDO ingestion (i.e. data
were collected between *90 and 150 min following
ingestion).
Indomethacin is one of many commonly used anti-
inflammatory non-steroids (e.g. aspirin, ibuprofen,
naproxen, sulindac), which inhibit prostaglandin synthesis
by reversible inhibition of fatty acid cyclooxygenase, an
important catalyst in the transformation of arachidonic
acid to prostaglandins. Parfenova et al. (1994, 1995b)
found, in newborn pigs, the normal increases in pial
arteriolar diameter and cortical cerebrospinal cAMP with
either iloprost (a prostacyclin receptor agonist) or hyper-
capnia were abolished or severely attenuated following
INDO; also, the cerebrovascular response to isoproterenol
(b-adrenoreceptor agonist) was unaffected. Since short-
term exposure to hypercapnia elevates cAMP in the
vascular smooth muscles both directly and indirectly via
prostaglandin-mediated endothelial pathways, resulting in
cerebrovascular dilation (Hsu et al. 1993; Parfenova and
Leffler 1996; Parfenova et al. 1994), such findings indi-
cate that INDO attenuates normal cerebrovascular CO2
reactivity via selective inhibition of both prostaglandin H
synthase and prostacyclin receptor-mediated responses
(Parfenova et al. 1995a, b; Wagerle and Degiulio 1994).
In support of this, Pickard et al. (1980) found the INDO-
induced reduction in cerebrovascular CO2 reactivity was
reversed with intracarotid prostacyclin infusion in
baboons. In addition, INDO has been shown to partially
Table 1 Baseline cerebrovascular, respiratory and arterial blood gas
variables before and after indomethacin
Control INDO
Cerebrovascular
MCAv (cm s-1) 70 ± 10 53 ± 15***
CVCi (cm s-1 mmHg-1) 0.86 ± 0.18 0.58 ± 0.18***
TOI (%) 71.7 ± 2.2 68.4 ± 3.7
Respiratory
_VE (L min
-1) 12.7 ± 3.5 12.7 ± 2.9
f (breaths min-1) 16 ± 4 15 ± 3
VT (L) 0.8 ± 0.4 0.9 ± 0.2
PETCO2 (mmHg) 39 ± 5 39 ± 4
PETO2 (mmHg) 107 ± 5 106 ± 5
Cardiovascular
HR (b min-1) 67 ± 10 60 ± 7***
MAP (mmHg) 84 ± 14 92 ± 13
Values are means ± SD
*** Different from control (P \ 0.001)
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inhibit lipopolysaccharide-induced dilation in the cere-
brovasculature (Brian et al. 1998).
Interestingly, studies have only reported reductions in
resting CBF and cerebrovascular responsiveness to CO2
following oral ingestion of INDO, but not aspirin, sulindac,
naproxen or ibuprofen (Eriksson et al. 1983; Markus et al.
1994; Parfenova et al. 1995b; Wagerle and Degiulio 1994).
This lack of change in basal CBF and cerebrovascular CO2
reactivity has led to speculations that these other non-ste-
roidal anti-inflammatory drugs may not cross the blood–
brain barrier sufficiently to alter cerebrovascular function
(Eriksson et al. 1983) or are less effective in the inhibition
of prostanoid-induced cAMP formation (Parfenova et al.
1995b). In support of this, both aspirin and ibuprofen failed
to inhibit the pial arteriolar dilation response to hyper-
capnia despite being effective in inhibiting prostanoids
synthesis (Parfenova et al. 1995b; Wagerle and Degiulio
1994). Moreover, Parfenova et al. (1995b) found, in con-
trast to INDO (5 mg kg-1 i.v.), aspirin (50 mg kg-1 i.v.)
failed to attenuate the prostacyclin receptor-mediated
increase in cAMP formation by the microvascular smooth
muscle and endothelial cells. The authors speculated that
the inhibition of prostanoids production is necessary, but
not sufficient, to block the prostanoids-induced cerebro-
vascular response to hypercapnia. Instead, inhibition of
both cortical prostanoids synthase and prostacyclin recep-
tor activation may be needed to blunt the cerebrovascular
CO2 reactivity. Alternatively, it is possible that INDO may
alter cerebrovascular function via non-prostaglandin path-
ways, such as inhibition of histamine release (Konig et al.
1987), calcium channel blockade (Northover 1977),
potentiation of lipoxygenase pathway (Docherty and
Wilson 1987), modification of extracellular pH (Wang
et al. 1993), INDO’s scavenging effect on inhibition of
superoxide generation (Pourcyrous et al. 1993), or via
increases in endothelin-1 (Therkelsen et al. 1994). Most
noteworthy is the finding by Wang et al. (1993), which
showed that INDO abolished the acetazolamide-induced
increase in CBF. Since acetazolamide is known to increase
cerebral acidosis via a carbonic anhydrase inhibition and
associated increase in CO2 retention, the authors conclude
that INDO acts to lower the cerebrovascular CO2 reactivity
by a non-prostaglandin-mediated mechanism that directly
interferes with the regulation of CBF and cerebrovascular
tone mediated by an increase in extracellular pH. However,
Hohimer et al. (1985) found INDO-induced reduction in
CBF increased the sagittal vein [H?]. Therefore, it seems
unlikely that INDO directly alters cerebral pH. More-
over, an increase in cerebral pH would attenuate, rather
than augment, the ventilatory response to hyperoxic
hypercapnia.
Assessment of CBF
In this study, transcranial Doppler ultrasound was used
to measure the MCAv as an index of global CBF
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responsiveness to CO2. Numerous studies have provided
evidence, which support the validity of MCAv as an index
of regional CBF (Bishop et al. 1986; Nuttall et al. 1996;
Peebles et al. 2008; Serrador et al. 2000; ter Minassian
et al. 1998; Valdueza et al. 1997). Moreover, studies have
shown that the MCA diameter is relatively unchanged in
the range of 23–60 mmHg for PaO2 (Giller et al. 1993;
Serrador et al. 2000; Valdueza et al. 1997). However,
evidence of unchanged MCA diameter during hypoxia is
still lacking. Nevertheless, it is noteworthy that the
observed MCAv response during isocapnic hypoxia was
comparable to findings by Noth et al. (2008), who have
previously assessed the CBF response to isocapnic hypoxia
using MRI (Noth et al. 2008). Importantly, consistent with
our observations (Fig. 2), these authors also reported high
intra-subject variability in CBF response to hypoxia (Noth
et al. 2008). Collectively, these findings support the use of
MCAv as a valid measure of CBF.
Influence of indomethacin on cerebrovascular reactivity
to CO2 and O2
Numerous human studies using transcranial Doppler
ultrasound (Ivancev et al. 2009; Markus et al. 1994; Xie
et al. 2006), MRI (Bruhn et al. 2001; St Lawrence et al.
2002), 133Xe method (Jensen et al. 1996) and N2O washout
method (Eriksson et al. 1983; Wennmalm et al. 1983) have
reported that INDO reduces basal CBF by 25–35% and
cerebrovascular CO2 reactivity by 50–60%. Consistent
with these reports, in the present study, INDO reduced
resting MCAv by 25% and blunted cerebrovascular CO2
reactivity by 46% during steady-state hyperoxic hyper-
capnia (Fig. 1). In contrast, Pickles et al. (1984) reported a
reduced basal CBF without any concurrent changes in
cerebrovascular CO2 reactivity in six participants following
2 days of INDO oral administration (100 mg day-1).
However, in that study, participants were given 50 mg of
INDO the morning of the experiment, whilst the present
and other previous studies (Bruhn et al. 2001; Eriksson
et al. 1983; Fan et al. 2010; Ivancev et al. 2009; Markus
et al. 1994; St Lawrence et al. 2002; Wennmalm et al.
1983; Xie et al. 2006, 2009) have assessed the effect of
INDO on the cerebrovascular CO2 reactivity following a
single larger dose of INDO (100 mg) 90 min prior to
measurement. Accordingly, these methodological differ-
ences make it difficult to compare the findings of the
Pickles et al. (1984) study.
Nishimura et al. (1987) have previously found a
reduction in the arterial-to-internal venous jugular PCO2
difference during 5–15 min of hypoxic exposure in healthy
humans. From this observation, they concluded that
hypoxia-induced increases in CBF would serve to increase
the H? washout from the brain, thereby modulating the
ventilatory drive during transient hypoxia. Importantly,
these findings highlight the role of cerebrovascular reac-
tivity to hypoxia in the modulation of hypoxic ventilatory
response. The effect of INDO on the control of hypoxia-
induced vasodilation in the cerebrovasculature has not been
examined in humans. Most (Armstead 2000; Coyle et al.
1993, 1995; Isozumi et al. 1994; Leffler and Parfenova
1997; Mollace et al. 1997; van Bel et al. 1997), but not all
(McCalden et al. 1984), animal studies have reported a
reduced cerebrovascular responsiveness to hypoxia with
INDO—presumably due to the inhibition of prostaglandin
production. Coyle et al. (1993, 1995) provided evidence to
indicate that INDO attenuates hypoxia-induced cerebral
vasodilation in a dose-dependent manner. They reported a
reduction in CBF with a high dosage of INDO (5 mg kg-1)
in pigs, whilst no changes were observed with low dosage
(0.3 mg kg-1). In the present study, INDO (*1.4 mg
kg-1) did not alter cerebrovascular responsiveness to iso-
capnic hypoxia (Fig. 2). Therefore, it seems reasonable to
assume that the physiological dosage of INDO used in the
present study was insufficient to cause any alterations in
the cerebrovascular responsiveness to hypoxia.
Effect of indomethacin on ventilatory sensitivity
to CO2 and O2
It has been shown in both human (Fan et al. 2010; Xie et al.
2006) and goat (Chapman et al. 1979a) studies that
reductions in both basal CBF and cerebrovascular CO2
reactivity increase the ventilatory responsiveness to
hyperoxic hypercapnia, presumably mediated by reduced
H? ion washout and associated increase in central che-
moreceptor activation. In the present study, INDO-induced
reduction in cerebrovascular CO2 reactivity enhanced the
ventilatory responsiveness to CO2 during hyperoxic
hypercapnia (Fig. 1). Importantly, the INDO-induced
increase in the ventilatory CO2 sensitivity in the present
study was comparable to those reported by Xie et al.
(2006). Since hyperoxia is known to silence the peripheral
chemoreceptor activity in most individuals (Cunningham
et al. 1963; Gardner 1980; Mohan and Duffin 1997), we
attributed this increase in _VE response to hyperoxic
hypercapnia associated with INDO to an enhanced central
chemoreflex.
An important consideration with regard to the use of
INDO to alter ventilatory control is the potential for
breathing effects through mechanisms other than at the
level of the central chemoreceptors. One hypothesis pro-
posed by Xie et al. (2009) is that INDO may selectively
enhance _VE by enhancing the peripheral chemoreflex (Xie
et al. 2009). As discussed in the introduction, the role of
INDO on the peripheral chemoreflex in humans is unclear.
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Xie et al. (2006) reported no difference in the _VE response
to CO2 under the condition of hyperoxia or normoxia fol-
lowing INDO ingestion (100 mg). From this finding, they
proposed that INDO does not influence the peripheral
chemoreflex in healthy resting humans. Likewise, Chap-
man et al. (1979a) found, using carotid artery clamping,
that the ventilatory response to transient hypoxia is unal-
tered with moderate reductions in basal CBF (30%) and
cerebrovascular CO2 reactivity in conscious goats. Con-
sistent with these findings, we did not observe any changes
in the _VE response to isocapnic hypoxia with INDO-
induced reduction in cerebrovascular CO2 reactivity
(Fig. 2), thus supporting a preserved peripheral chemore-
flex following INDO. Taken together, data from the present
study indicate that INDO selectively enhances the central
chemoreflex in humans without any concurrent alterations
in the peripheral chemoreflex.
Another important consideration is the effect of INDO
on cerebral oxygenation. Chapman et al. (1979a) reported a
blunted ventilatory response to both hypercapnia and
transient hypoxia with severe reductions in CBF (50%),
and near abolishment of cerebrovascular CO2 reactivity
blunts the hypoxic ventilatory response. They attributed the
latter finding to respiratory neuron depression associated
with severe cerebral ischaemia. In the present study, we did
not observe a reduction in cerebral oxygenation with INDO
administration in healthy adults (Table 1). In contrast,
previous studies have shown that INDO-induced reduction
in basal CBF lowers cellular oxygenation of brain tissues in
both preterm infants with ductus arteriosus (Benders et al.
1995; Lemmers et al. 2008; Liem et al. 1994) and newborn
piglets (Yamashita et al. 1999). Whilst the discrepancies
between these findings are unclear, it is possible that INDO
may have differential effect on cerebral oxygenation
between adults and preterm infants. Consistent with this
suggestion, during conditions of hypotension (Lucas et al.
2010), exercise (Ainslie et al. 2007) and heat stress (Fan
et al. 2008), there have been reports of a maintained
cerebral oxygenation despite reductions in MCAv. We
acknowledge, however, that since cerebral oxygenation
was measured in only seven participants, the effect of
INDO on cerebral oxygenation could potentially be
masked by insufficient statistical power.
Implications
An observational study by Xie et al. (2005) demonstrated
that congestive heart failure patients with central sleep
apnoea display a lower cerebrovascular responsiveness to
CO2 compared to patients without central sleep apnoea.
Similarly, Reichmuth et al. (2009) found that patients with
obstructive sleep apnoea have impaired cerebrovascular
function. Recent studies have demonstrated that a single
dose of INDO causes breathing instability during wake-
fulness (Fan et al. 2010), increases the risk of central
apnoea (Xie et al. 2009) and augments obstructive sleep
apnoea (Burgess et al. 2010). The findings from the present
study (Fig. 2) indicate that these INDO-induced increases
in breathing instability during both wakefulness and sleep
are mediated by its influence on the central chemoreceptor
activation, rather than any additional changes in the
peripheral chemoreflex. Such findings support the role of a
blunted cerebrovascular CO2 reactivity in the pathogenesis
of breathing instability.
Conclusion
Together with previous studies (Bruhn et al. 2001; Eriksson
et al. 1983; Fan et al. 2010; Ivancev et al. 2009; Kastrup
et al. 1999; Markus et al. 1994; St Lawrence et al. 2002;
Wennmalm et al. 1983; Xie et al. 2006, 2009), data from
the present study indicate that a single dose of INDO
(100 mg) selectively lowers CBF and blunts the cerebro-
vascular CO2 reactivity without any concurrent changes in
the cerebrovascular and ventilatory responses to hypoxia in
healthy humans.
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